newsfilter
← Latest News
GlobeNewswire·

Cullinan Therapeutics Advances Velinotamig into Global Clinical Development for Autoimmune Cytopenias Following IND Clearance by the U.S. FDA

Global regulatory clearances in the U.S. and Australia support initiation of a Phase 1b/2a study in relapsing and refractory ITP and wAIHA Study expands immunology portfolio into autoimmune cytopenias, evaluating a